Diagnosis and management of pleural infection.

IF 2.3 Q2 RESPIRATORY SYSTEM
Breathe Pub Date : 2023-12-01 Epub Date: 2024-01-16 DOI:10.1183/20734735.0146-2023
Alguili Elsheikh, Malvika Bhatnagar, Najib M Rahman
{"title":"Diagnosis and management of pleural infection.","authors":"Alguili Elsheikh, Malvika Bhatnagar, Najib M Rahman","doi":"10.1183/20734735.0146-2023","DOIUrl":null,"url":null,"abstract":"<p><p>Pleural infection remains a medical challenge. Although closed tube drainage revolutionised treatment in the 19th century, pleural infection still poses a significant health burden with increasing incidence. Diagnosis presents challenges due to non-specific clinical presenting features. Imaging techniques such as chest radiographs, thoracic ultrasound and computed tomography scans aid diagnosis. Pleural fluid analysis, the gold standard, involves assessing gross appearance, biochemical markers and microbiology. Novel biomarkers such as suPAR (soluble urokinase plasminogen activator receptor) and PAI-1 (plasminogen activator inhibitor-1) show promise in diagnosis and prognosis, and microbiology demonstrates complex microbial diversity and is associated with outcomes. The management of pleural infection involves antibiotic therapy, chest drain insertion, intrapleural fibrinolytic therapy and surgery. Antibiotic therapy relies on empirical broad-spectrum antibiotics based on local policies, infection setting and resistance patterns. Chest drain insertion is the mainstay of management, and use of intrapleural fibrinolytics facilitates effective drainage. Surgical interventions such as video-assisted thoracoscopic surgery and decortication are considered in cases not responding to medical therapy. Risk stratification tools such as the RAPID (renal, age, purulence, infection source and dietary factors) score may help guide tailored management. The roles of other modalities such as local anaesthetic medical thoracoscopy and intrapleural antibiotics are debated. Ongoing research aims to improve outcomes by matching interventions with risk profile and to better understand the development of disease.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10790177/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breathe","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1183/20734735.0146-2023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/16 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Pleural infection remains a medical challenge. Although closed tube drainage revolutionised treatment in the 19th century, pleural infection still poses a significant health burden with increasing incidence. Diagnosis presents challenges due to non-specific clinical presenting features. Imaging techniques such as chest radiographs, thoracic ultrasound and computed tomography scans aid diagnosis. Pleural fluid analysis, the gold standard, involves assessing gross appearance, biochemical markers and microbiology. Novel biomarkers such as suPAR (soluble urokinase plasminogen activator receptor) and PAI-1 (plasminogen activator inhibitor-1) show promise in diagnosis and prognosis, and microbiology demonstrates complex microbial diversity and is associated with outcomes. The management of pleural infection involves antibiotic therapy, chest drain insertion, intrapleural fibrinolytic therapy and surgery. Antibiotic therapy relies on empirical broad-spectrum antibiotics based on local policies, infection setting and resistance patterns. Chest drain insertion is the mainstay of management, and use of intrapleural fibrinolytics facilitates effective drainage. Surgical interventions such as video-assisted thoracoscopic surgery and decortication are considered in cases not responding to medical therapy. Risk stratification tools such as the RAPID (renal, age, purulence, infection source and dietary factors) score may help guide tailored management. The roles of other modalities such as local anaesthetic medical thoracoscopy and intrapleural antibiotics are debated. Ongoing research aims to improve outcomes by matching interventions with risk profile and to better understand the development of disease.

胸膜感染的诊断和处理。
胸膜感染仍然是一项医学挑战。尽管 19 世纪的闭式管道引流术彻底改变了治疗方法,但胸膜感染仍对健康造成重大负担,且发病率不断上升。由于临床表现特征不具特异性,诊断面临挑战。胸片、胸部超声波和计算机断层扫描等成像技术有助于诊断。胸腔积液分析是金标准,包括评估大体外观、生化标志物和微生物学。suPAR(可溶性尿激酶纤溶酶原激活物受体)和PAI-1(纤溶酶原激活物抑制剂-1)等新型生物标志物在诊断和预后方面显示出前景,而微生物学则显示出复杂的微生物多样性并与预后相关。胸膜感染的治疗包括抗生素治疗、插入胸腔引流管、胸膜内纤维蛋白溶解治疗和手术。抗生素治疗主要根据当地政策、感染环境和耐药模式,采用经验性广谱抗生素。插入胸腔引流管是治疗的主要方法,使用胸膜内纤维蛋白溶解剂有助于有效引流。对于药物治疗无效的病例,可考虑采取外科干预措施,如视频辅助胸腔镜手术和去栓术。RAPID(肾脏、年龄、脓液、感染源和饮食因素)评分等风险分层工具可帮助指导有针对性的治疗。对局部麻醉胸腔镜和胸膜腔内抗生素等其他方式的作用还存在争议。正在进行的研究旨在通过将干预措施与风险状况相匹配来改善治疗效果,并更好地了解疾病的发展过程。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Breathe
Breathe RESPIRATORY SYSTEM-
CiteScore
2.90
自引率
5.00%
发文量
51
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信